melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The treatment by gavage with a mixture of fish and soybean oils (1:1 ratio) both reduced the melanoma growth and the levels of leukotriene B<sub>4</sub> (LTB<sub>4</sub>), prostaglandin E<sub>2</sub> (PGE<sub>2</sub>), PGE<sub>2</sub>/prostaglandin E<sub>3</sub> (PGE<sub>3</sub>) ratio, and CXC ligand 1 (CXCL1) and increased the levels of interleukin 10 (IL-10) to IL-10/CXCL1 ratio in the melanoma microenvironment.
|
31374840 |
2019 |
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The main predisposition of PMN formation in melanoma lies in the pulmonary recruitment of granulocytic myeloid-derived suppressor cells (G-MDSCs, CD11b<sup>+</sup>Ly6G<sup>+</sup> cells) induced by tumors, which increase vascular permeability by secreting matrix metalloproteinase-9 (MMP-9) and result in immunosuppression by secreting interleukin-10 (IL-10) in premetastatic lungs.
|
31823615 |
2019 |
melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Melanoma differentiation associated gene-7 (<i>mda-7/IL-24</i>) is a member of the IL-10 family of cytokines, with ubiquitous direct and "bystander" tumor-selective killing properties.
|
31489119 |
2019 |
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Other studies have provided evidence that interleukin-10 (IL-10) neutralizing antibodies (αIL-10) enhance immunologic melanoma therapies by modulating the tolerogenic tumor microenvironment.
|
29334492 |
2018 |
melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This meta-analysis showed that the -592A/C and 1082G/A IL-10 polymorphisms might not be risk factors for melanoma or for BCC and sSCC patients, but we obtained a correlation between skin cancer risk and the IL-10 -819T/C polymorphism.
|
30427744 |
2018 |
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We studied cytokine profile of cellular Th1 (IL-2, IL-12, IFN-γ) and humoral Th2 (IL-4, IL-10) immune response, vascular endothelial growth factor (VEGFA), transforming growth factor-β 2 (TGF-β 2), S100 protein (S100A1B and S100BB), adhesion molecule CD44 and serum cytokines β2-microglobulin to analyze different peripheral blood mononuclear cell subpopuations of patients treated with dendritic vaccines and/or cyclophosphamide in melanoma patients in the course of adjuvant treatment.
|
29849947 |
2018 |
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A decrease in TNF-α, IL-4, IL-5, IL-6, and IL-10 serum levels was observed in the GK-1/anti-PD-L1 combination group that may explain the beneficial effects of the combination treatment in prolonging the life of mice bearing melanoma.
|
28301259 |
2017 |
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the present work, we found that the C57BL/6 mice, inoculated with B16F10 cells that were co-cultivated with B-1 lymphocytes from IL-10 knockout mice, developed fewer metastatic nodules than the ones which were injected with the melanoma cells that were cultivated in the presence of wild-type B-1 cells.
|
29145406 |
2017 |
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Melanoma differentiation associated gene-7/Interleukin-24 (MDA-7/IL-24) is a novel member of the IL-10 gene family that selectively induces apoptosis and toxic autophagy in a broad spectrum of human cancers, including breast cancer, without harming normal cells or tissues.
|
26474456 |
2015 |
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Role of IL-10 and TGF-β in melanoma.
|
25565012 |
2015 |
melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our analysis suggests that the IL-10-3575T>A mutation may associate with melanoma and DLBCL and exert a differential effect in different cancer sites.
|
25955784 |
2015 |
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
There were no differences in IL-10 mRNA levels between any of the 3 melanoma cell lines tested and normal melanocytes.
|
26631117 |
2015 |
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We discovered novel associations of IL10 with melanoma survival at 1q32.1, suggesting this locus should be considered as a novel melanoma prognostic biomarker with potential for aiding melanoma patient management.
|
25604082 |
2015 |
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Reduced melanoma growth is associated with significant increases in MHCII and IL12 expression in tumor-associated macrophages and with >90% reductions in IL10 expression in tumor-associated macrophages, dendritic cells (DC), and Ly6C(+) or Ly6G(+) myeloid-derived suppressor cells (MDSC).
|
25377469 |
2014 |
melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Melanoma differentiation-associated gene (MDA)-7)/interleukin (IL)-24, a member of the IL-10 family of cytokines, inhibits growth of various human cancer cells, yet the underlying mechanism is largely unknown.
|
23468528 |
2013 |
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Regulatory T-cell depletion and IL-10 neutralization led to increased occurrence of vitiligo that correlated with a decreased incidence of melanoma metastases.
|
23878221 |
2013 |
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results indicate that Wnt/β-catenin pathways in human melanoma may be involved in immunosuppression and immunoresistance in both induction and effector phases of antitumor immunoresponses partly through IL-10 production, and they may be attractive targets for restoring immunocompetence in patients with Wnt/β-catenin-activated melanoma.
|
22815287 |
2012 |
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Gene therapy with interleukin-10 receptor and interleukin-12 induces a protective interferon-γ-dependent response against B16F10-Nex2 melanoma.
|
20885448 |
2011 |
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In a logistic regression model, moderate-to-high IL-10 mRNA expression by tumor cells was significantly associated with vertical growth-phase melanoma.
|
21317876 |
2011 |
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our previous works have shown that IL-10 and IFNγ co-regulate indoleamine-2,3-dioxygenase (IDO)-expressing immunosuppressive dendritic cells (DCs) in melanoma SLNs.
|
21327637 |
2011 |
melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24) is a unique member of the IL-10 gene family that displays nearly ubiquitous cancer-specific toxicity, with no harmful effects toward normal cells or tissues. mda-7/IL-24 was cloned from human melanoma cells by differentiation induction subtraction hybridization (DISH) and promotes endoplasmic reticulum (ER) stress culminating in apoptosis or toxic autophagy in a broad-spectrum of human cancers, when assayed in cell culture, in vivo in human tumor xenograft mouse models and in a Phase I clinical trial in patients with advanced cancers.
|
20926331 |
2010 |
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
IL-24, previously known as melanoma differentiation antigen 7 (mda-7), is a member of the IL-10 family of cytokines and is mainly produced by Th2 cells and activated monocytes.
|
20712572 |
2010 |
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Melanoma differentiation associated gene-7/interleukin 24 (mda-7/IL-24) is a unique interleukin (IL)-10 family cytokine displaying selective apoptosis-inducing activity in transformed cells without harming normal cells.
|
19910452 |
2010 |
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Melanoma differentiation-associated gene 7 (mda-7)/interleukin-24 (IL-24) is a unique member of the IL-10 gene family, which displays a broad range of antitumor properties, including induction of cancer-specific apoptosis.
|
20406981 |
2010 |
melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Although our findings need to be confirmed by independent and larger multicenter studies, we have described for the first time the association of distal gene variants of the IL-10 gene as an independent risk factor for melanoma.
|
19458621 |
2009 |